Blood test Shows Promise in Detecting Colon Cancer Relapse

Valencia,Spain (2025-05-04) – A new blood test,Tav16,demonstrates the ability to detect minimal residual disease in ⁢colon cancer patients ‍after surgery,according to research published in Nature Cancer. The ‍test, developed by researchers⁢ at the Inclusive Health Research Institute of the University ⁤Clinical‍ Hospital of⁢ Valencia, could lead to earlier identification of relapses and more personalized treatment plans.

Tav16 Test Details

The study⁣ focused on ⁤patients with stage II and III colon cancer. Researchers aimed to improve relapse prediction through a non-invasive method. The Tav16 test analyzes circulating tumor DNA (ctDNA) by sequencing ‍the full exome.‍ This allows for the ⁤identification of residual disease with ⁣high sensitivity, ⁢potentially before it is indeed detectable through imaging techniques.

Study methodology and Findings

Samples where analyzed at three key points: diagnosis, post-surgery, ⁤and ⁣relapse. The ⁣study included⁢ 25⁢ patients in ⁢Spain and was validated with 15 patients⁢ in Denmark. Researchers also incorporated transcriptomic and proteomic analyses to investigate tumor progression. A key finding suggests that immune evasion in early stages of colon cancer might potentially be a determining factor in relapses, potentially opening the door for immunotherapy in ⁣initial stages of the disease.

Research Leadership

The study was⁣ led by Dr. ‍Noelia Tarazona and Dr. ⁤Andrés Cervantes, both ⁢researchers from the Biomedical Research Center Cancer (CIBERONC) of⁣ the Carlos III Health Institute. Jorge Martín Arana, the lead author of the publication, developed⁣ his doctoral thesis on this work, along⁢ with Francisco Gimeno Valiente and a multidisciplinary team.

Infrastructure and International Collaboration

key infrastructure included Kobonco’s Precision Medicine unit and the Bioinformatics Unit of Incliva. The Coloproctology Team of the Clinical Hospital also participated. International validation was coordinated by Dr. Claus Lindbjerg⁣ Andersen at the Department of ⁣Molecular Medicine of Aarhus University Hospital in Denmark, with support from the Danish ⁣Cancer Biobank and the Colorectal Cancer Research Biobank.

The Clinical challenge of Colorectal Cancer

Colorectal cancer is the third most frequent tumor worldwide and the second leading cause of cancer death, with approximately two million cases annually. In Spain, more than 44,000 cases are diagnosed each⁣ year. Current therapeutic decisions after surgery‍ are primarily based on pathological anatomy. However, up to⁤ 40% of patients relapse despite being considered cured, and between 60% and 70% receive ⁢unnecessary chemotherapy, according to researchers.

Tav16’s Potential Impact

The Tav16 test ⁢can anticipate the risk of relapse without requiring⁣ a sample of the original tumor. It demonstrates a⁢ sensitivity of 87% to 100%, positioning it as a key tool in precision medicine.The technology is patent-protected and considered suitable for future clinical transfer.Funding for‍ the ‍project came from various sources, including the Carlos III Health Institute, the Spanish Society of Medical Oncology (SEOM), the TTD group, the Valencian Generalitat, Feder⁢ Funds, the Novo Nordisk Foundation, and the Danish‍ Society against Cancer.

Colorectal Cancer Screening Recommendations

The U.S. Preventive Services Task ⁤Force (USPSTF) recommends that all adults⁤ aged 45 to 75 be screened for colorectal cancer.⁣ Medicare Part B covers blood-based biomarker screening tests for those between 45 and 85 who ⁢show no symptoms of colorectal disease.

Blood Test‍ for ‍Colon Cancer Relapse: Your Questions Answered

What is the Tav16 blood test?

The⁤ Tav16 blood test is a new diagnostic tool developed by researchers at the Inclusive Health Research Institute of the University Clinical Hospital of Valencia. It’s designed⁤ to detect minimal residual disease in colon cancer patients after surgery. This non-invasive ⁢test ⁢analyzes circulating tumor ⁣DNA (ctDNA) in the⁣ blood.

How does the Tav16 test work?

The⁤ Tav16 test analyzes circulating tumor DNA (ctDNA) by sequencing the full exome. This method allows for ⁢the identification of residual disease ‍with high sensitivity. This can potentially identify the ‍presence of cancer relapse earlier than traditional imaging techniques.

Who developed the Tav16 test?

The ⁣Tav16 test ⁤was developed by researchers at the Inclusive Health Research Institute of the University Clinical Hospital ⁣of Valencia, spain. The study was led by Dr. Noelia Tarazona and Dr. Andrés Cervantes.

What stage of‍ colon cancer was the study⁣ focused on?

The study focused on patients ⁤with stage II and III colon cancer.

What were the key findings‍ of the Tav16 study?

A key finding suggests that immune evasion in early stages of colon cancer might⁢ potentially‍ be a determining factor in relapses. The test demonstrated a⁤ sensitivity ‍of ‍87% to 100% in detecting⁢ minimal residual disease.

Were was the ⁣study conducted?

The ‍study included 25 patients in⁣ spain and was validated with an additional 15 patients ⁣in Denmark.

What is the potential impact of the Tav16 test?

The Tav16 test ⁣can definitely help ⁤anticipate the risk of relapse without‍ requiring a sample of the original tumor. It could lead to earlier identification of⁢ relapses and more personalized treatment plans. It is also patent-protected, and considered suitable for future clinical transfer.

What ⁣are the current challenges in ⁤treating colorectal cancer?

Colorectal cancer is⁣ the third most⁢ frequent tumor worldwide and the second leading cause of cancer death. Up⁢ to 40% of patients relapse after surgery,despite being considered cured.Furthermore, according to ⁢researchers, between 60% and 70% of patients receive needless chemotherapy.

What are the colorectal ⁢cancer screening recommendations?

The U.S. Preventive Services⁤ Task Force (USPSTF) recommends that all adults aged 45 to 75 be screened for colorectal⁤ cancer. Medicare‍ Part B covers ⁣blood-based biomarker screening tests for those between 45 and 85 who show no symptoms of colorectal disease.

What funding sources supported the Tav16 project?

funding ⁣for the project⁢ came‍ from various sources, including:

⁤ Carlos⁢ III Health Institute

‍ Spanish Society of Medical ⁤oncology (SEOM)

TTD group

‍Valencian Generalitat

Feder Funds

Novo ⁤Nordisk ⁢Foundation

* ⁣ Danish Society against Cancer

where was the international validation ‍of the test coordinated?

International validation was ⁢coordinated by Dr. Claus Lindbjerg Andersen⁣ at the Department of Molecular Medicine ⁤of Aarhus University Hospital in denmark.

What is precision medicine?

Precision medicine is a medical approach that uses facts about a person’s⁣ genes, environment, and lifestyle to prevent, diagnose, and treat disease. The Tav16 test is considered a key‍ tool in precision medicine.

Key Features of the Tav16 Blood Test

Here’s a ⁤summary of the key features of‍ the Tav16 ⁢blood ⁤test:

| Feature ⁢ ⁤ ⁣ ‍ | Description ⁣ ‍ ⁤ ⁢ ⁣ ⁣ ⁣|

| ———————– | ————————————————————————————————– |

| Purpose | Detects minimal residual disease in colon cancer patients after surgery. ⁢ ‍ ⁤ |

| Method ⁣ | Analyzes circulating tumor DNA (ctDNA) by sequencing the full exome.|

| Patient Focus ⁢ ‍ ⁤ | Patients with stage II ‍and III colon cancer. ⁢ ⁤ ‍ |

| ⁤Sensitivity | 87% to 100% ‍ ⁢ ⁣ ⁣ ⁣ ⁤ ‍ ‍ ⁢ |

| Potential Impact ‍ ⁢ | Earlier ⁢relapse detection, more personalized⁣ treatment. ⁣ ⁢ ⁣ ⁤ ⁣ |

| Advantages | Non-invasive method. ‍ ⁢‍ ⁣ ⁢ ⁣ ⁣ ‍ ⁣ ⁢ |

| Funding ⁣Sources⁣ | Carlos III Health Institute, SEOM, TTD group, Valencian Generalitat, Feder Funds, Novo Nordisk Foundation,‍ Danish society against Cancer |